Imlunestrant treatment for ER-positive HER2-negative breast cancer with ESR1 mutation

FDA-Zulassung von Imlunestrant für ER-positive, HER2-negative, ESR1-mutierte Brustkrebserkrankungen

FDA Approval of Imlunestrant for ESR1-Mutated Breast Cancer

Lenus Health
0 Kommentare